If-csatorna-gátlás - Új lehetoség az ischaemiás szívbetegség kezelésében

Translated title of the contribution: If-channel inhibition - A new approach in the treatment of ischaemic heart disease

Research output: Contribution to journalReview article

Abstract

Life span, body mass and metabolic rate are strongly related to resting heart rate. Several studies suggest that the reduction of heart rate has a beneficial effect on cardiac morbidity and mortality. Ivabradine, the first selective and specific If-channel inhibitor, has a novel and unique mode of action on cardiac pacemaker activity. It acts at the core of heart rate regulation by specifically binding to the f-channel of the sinus node cell and selectively inhibiting the If (funny) current. Praeclinical studies have convincingly proved that this drug reduces heart rate without any adverse electrophysiologic or haemodynamic side effects.

Translated title of the contributionIf-channel inhibition - A new approach in the treatment of ischaemic heart disease
Original languageHungarian
Pages (from-to)21-24
Number of pages4
JournalLege Artis Medicinae
Volume17
Issue numberSUPPL. 1
Publication statusPublished - Jun 11 2007

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'I<sub>f</sub>-channel inhibition - A new approach in the treatment of ischaemic heart disease'. Together they form a unique fingerprint.

  • Cite this